{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:17:51Z","timestamp":1792271871528,"version":"4.4.0"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2018YFC1704901"],"award-info":[{"award-number":["2018YFC1704901"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.phrs.2019.104577","type":"journal-article","created":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T11:47:23Z","timestamp":1575028043000},"page":"104577","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["Role of cardioprotective agents on chemotherapy-induced heart failure: A systematic review and network meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"151","author":[{"given":"Xinye","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanda","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiansong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingjiang","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfei","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongcai","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanwei","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2019.104577_bib0005","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002661","article-title":"Cancer therapy-related cardiac dysfunction and heart failure: part 1: definitions, pathophysiology, risk factors, and imaging","volume":"9","author":"Bloom","year":"2016","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.phrs.2019.104577_bib0010","doi-asserted-by":"crossref","first-page":"R64","DOI":"10.1186\/bcr2901","article-title":"Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study","volume":"13","author":"Patnaik","year":"2011","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.phrs.2019.104577_bib0015","first-page":"271","article-title":"Cancer treatment and survivorship statistics, 2016","volume":"66","author":"Miller","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.phrs.2019.104577_bib0020","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/eurheartj\/ehs181","article-title":"Cancer drugs and the heart: importance and management","volume":"34","author":"Suter","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2019.104577_bib0025","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1136\/heartjnl-2017-312103","article-title":"Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention","volume":"104","author":"Henriksen","year":"2018","journal-title":"Heart"},{"key":"10.1016\/j.phrs.2019.104577_bib0030","first-page":"21","article-title":"Cardiac risk in the treatment of breast cancer: assessment and management","volume":"7","author":"Valachis","year":"2015","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"10.1016\/j.phrs.2019.104577_bib0035","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1161\/01.CIR.0000130926.51766.CC","article-title":"Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy","volume":"109","author":"Cardinale","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2019.104577_bib0040","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s10549-014-3029-0","article-title":"Cardiovascular events, early discontinuation of trastuzumab, and their impact on survival","volume":"146","author":"Wang","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.phrs.2019.104577_bib0045","first-page":"168","article-title":"The 2012 Canadian Cardiovascular Society heart failure management guidelines update: focus on acute and chronic heart failure","volume":"29","author":"Mckelvie","year":"2013","journal-title":"Can. J. Cardiol."},{"issue":"30","key":"10.1016\/j.phrs.2019.104577_bib0050","first-page":"249","article-title":"The 2013 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: focus on rehabilitation and exercise and surgical coronary revascularization","author":"Moe","year":"2014","journal-title":"Can. J. Cardiol."},{"issue":"18","key":"10.1016\/j.phrs.2019.104577_bib0055","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"2016","author":"Ponikowski","year":"2016","journal-title":"Eur. J. Heart Fail."},{"issue":"128","key":"10.1016\/j.phrs.2019.104577_bib0060","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1161\/CIR.0b013e31829e8807","article-title":"ACCF\/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"2013","author":"Yancy","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2019.104577_bib0065","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","article-title":"Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial","volume":"71","author":"Avila","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2019.104577_bib0070","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.phrs.2019.104577_bib0075","series-title":"Cochrane Handbook for Systematic Reviews of Interventions (Version 5.1.0). March, 2011","author":"The Cochrane Collaboration","year":"2018"},{"key":"10.1016\/j.phrs.2019.104577_bib0080","series-title":"Cochrane Methods","article-title":"A revised tool for assessing risk of bias in randomized trials","author":"Higgins","year":"2016"},{"key":"10.1016\/j.phrs.2019.104577_bib0085","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.phrs.2019.104577_bib0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2019.104577_bib0095","series-title":"Using Stata for Standard Pairwise and Network Meta-Analysis. Multiple-Treatments Meta-Analysis","year":"2018"},{"key":"10.1016\/j.phrs.2019.104577_bib0100","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/0962280207080643","article-title":"Evaluation of networks of randomized trials","volume":"17","author":"Salanti","year":"2008","journal-title":"Stat. Methods Med. Res."},{"key":"10.1016\/j.phrs.2019.104577_bib0105","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jclinepi.2014.08.012","article-title":"Predictive distributions were developed for the extent of heterogeneity in meta-analyses of continuous outcome data","volume":"68","author":"Rhodes","year":"2015","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.phrs.2019.104577_bib0110","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/ije\/dys041","article-title":"Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews","volume":"41","author":"Turner","year":"2012","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.phrs.2019.104577_bib0115","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Res. Synth. Methods"},{"key":"10.1016\/j.phrs.2019.104577_bib0120","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat. Med."},{"key":"10.1016\/j.phrs.2019.104577_bib0125","series-title":"Confidence in Network Meta-Analysis [computer program]","year":"2017"},{"key":"10.1016\/j.phrs.2019.104577_bib0130","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.jacc.2011.05.025","article-title":"Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy","volume":"58","author":"Acar","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2019.104577_bib0135","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/ejhf.196","article-title":"Protective effects of spironolactone against anthracycline-induced cardiomyopathy","volume":"17","author":"Akpek","year":"2015","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.phrs.2019.104577_bib0140","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/jamaoncol.2016.1726","article-title":"Angiotensin II-Receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: a randomized clinical trial","volume":"2","author":"Boekhout","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.phrs.2019.104577_bib0145","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","volume":"61","author":"Bosch","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2019.104577_bib0150","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","article-title":"Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition","volume":"114","author":"Cardinale","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2019.104577_bib0155","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/2193-1801-2-198","article-title":"Long-term, up to 18 months, protective effects of the angiotensin II receptor blocker telmisartan on Epirubin-induced inflammation and oxidative stress assessed by serial strain rate","volume":"2","author":"Dessi","year":"2013","journal-title":"Springerplus"},{"key":"10.1016\/j.phrs.2019.104577_bib0160","doi-asserted-by":"crossref","first-page":"509","DOI":"10.5603\/CJ.a2013.0150","article-title":"Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: a prospective randomized controlled study with six-month follow-up","volume":"21","author":"Elitok","year":"2014","journal-title":"Cardiol. J."},{"key":"10.1016\/j.phrs.2019.104577_bib0165","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/ajh.21840","article-title":"Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up","volume":"85","author":"Georgakopoulos","year":"2010","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.phrs.2019.104577_bib0170","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 x 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"37","author":"Gulati","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2019.104577_bib0175","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27308","article-title":"Role of ACE inhibitors in anthracycline-induced cardiotoxicity: a randomized, double-blind, placebo-controlled trial","volume":"65","author":"Gupta","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.phrs.2019.104577_bib0180","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s12012-016-9365-z","article-title":"Effect of enalapril on preventing anthracycline-induced cardiomyopathy","volume":"17","author":"Janbabai","year":"2017","journal-title":"Cardiovasc. Toxicol."},{"key":"10.1016\/j.phrs.2019.104577_bib0185","doi-asserted-by":"crossref","first-page":"725","DOI":"10.4103\/ijmr.IJMR_1323_14","article-title":"Preventive role of carvedilol in adriamycin-induced cardiomyopathy","volume":"144","author":"Jhorawat","year":"2016","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.phrs.2019.104577_bib0190","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.jacc.2006.07.052","article-title":"Protective effects of carvedilol against anthracycline-induced cardiomyopathy","volume":"48","author":"Kalay","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2019.104577_bib0195","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.ijcard.2012.06.023","article-title":"Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study","volume":"167","author":"Kaya","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.phrs.2019.104577_bib0200","first-page":"936","article-title":"Preventive effect of low-dose carvedilol combined with candesartan on the cardiotoxicity of anthracycline drugs in the adjuvant chemotherapy of breast cancer","volume":"35","author":"Liu","year":"2013","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"10.1016\/j.phrs.2019.104577_bib0205","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/FJC.0000000000000470","article-title":"Cardioprotective effects of carvedilol in inhibiting doxorubicin-induced cardiotoxicity","volume":"69","author":"Nabati","year":"2017","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.phrs.2019.104577_bib0210","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","article-title":"Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity","volume":"35","author":"Pituskin","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2019.104577_bib0215","first-page":"1052","article-title":"Can the epirubicin cardiotoxicity in cancer patients be prevented by angiotensin converting enzyme inhibitors?","volume":"18","author":"Radulescu","year":"2013","journal-title":"J. BUON"},{"key":"10.1016\/j.phrs.2019.104577_bib0220","doi-asserted-by":"crossref","first-page":"95","DOI":"10.15420\/ahhj.2011.9.2.95","article-title":"Protective effect of carvedilol in cardiomyopathy caused by anthracyclines in patients suffering from breast cancer and lymphoma","volume":"9","author":"Salehi","year":"2011","journal-title":"Am. Heart Hosp. J."},{"key":"10.1016\/j.phrs.2019.104577_bib0225","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000442722","article-title":"Carvedilol administration can prevent doxorubicin-induced cardiotoxicity: a double-blind randomized trial","volume":"134","author":"Tashakori Beheshti","year":"2016","journal-title":"Cardiology"},{"key":"10.1016\/j.phrs.2019.104577_bib0230","first-page":"302","article-title":"Chronic statin administration may attenuate early anthracycline-associated declines in left ventricular ejection function","volume":"31","author":"Chotenimitkhun","year":"2015","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.phrs.2019.104577_bib0235","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1016\/j.ejca.2013.04.030","article-title":"Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis","volume":"49","author":"Kalam","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.phrs.2019.104577_bib0240","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1136\/postgradmedj-2015-133535","article-title":"Cardioprotective role of beta-blockers and angiotensin antagonists in early-onset anthracyclines-induced cardiotoxicity in adult patients: a systematic review and meta-analysis","volume":"91","author":"Yun","year":"2015","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.phrs.2019.104577_bib0245","article-title":"Protective role of beta-blockers in chemotherapy-induced cardiotoxicity-a systematic review and meta-analysis of carvedilol","author":"Huang","year":"2018","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.phrs.2019.104577_bib0250","first-page":"831","article-title":"Canadian cardiovascular society guidelines for evaluation and management of cardiovascular complications of cancer therapy","volume":"32","author":"Virani","year":"2016","journal-title":"Can. J. Cardiol."},{"issue":"37","key":"10.1016\/j.phrs.2019.104577_bib0255","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"2016","author":"Zamorano","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2019.104577_bib0260","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1161\/CIRCHEARTFAILURE.112.000055","article-title":"Cardioprotective effect of beta-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure","volume":"6","author":"Seicean","year":"2013","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.phrs.2019.104577_bib0265","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.taap.2004.04.005","article-title":"Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity","volume":"200","author":"Oliveira","year":"2004","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.phrs.2019.104577_bib0270","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1016\/j.jacc.2018.03.461","article-title":"Beta-blockers for primary prevention of anthracycline cardiotoxicity: not quite ready for prime time","volume":"71","author":"Asnani","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2019.104577_bib0275","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.jacc.2003.08.008","article-title":"Aldosterone antagonism and myocardial infarction: from animals to man and back","volume":"42","author":"Solomon","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2019.104577_bib0280","series-title":"Lisinopril or Carvedilol for Prevention of Trastuzumab Induced Cardiotoxicity on 11 March 2018","author":"Guglin","year":"2018"},{"key":"10.1016\/j.phrs.2019.104577_bib0285","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ccl.2013.09.002","article-title":"The renin-angiotensin-aldosterone system and heart failure","volume":"32","author":"Sayer","year":"2014","journal-title":"Cardiol. Clin."},{"key":"10.1016\/j.phrs.2019.104577_bib0290","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(07)60242-6","article-title":"Renin-angiotensin system and cardiovascular risk","volume":"369","author":"Schmieder","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2019.104577_bib0295","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s40256-016-0173-4","article-title":"Unraveling the pivotal role of bradykinin in ACE inhibitor activity","volume":"16","author":"Taddei","year":"2016","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.phrs.2019.104577_bib0300","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/jamainternmed.2014.348","article-title":"Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis","volume":"174","author":"Cheng","year":"2014","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.phrs.2019.104577_bib0305","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","article-title":"Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials","volume":"67","author":"Xie","year":"2016","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.phrs.2019.104577_bib0310","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s12872-017-0686-z","article-title":"Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials","volume":"17","author":"Tai","year":"2017","journal-title":"BMC Cardiovasc. Disord."},{"key":"10.1016\/j.phrs.2019.104577_bib0315","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1161\/CIRCULATIONAHA.106.659763","article-title":"Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota","volume":"115","author":"Lam","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2019.104577_bib0320","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1161\/CIRCULATIONAHA.110.011031","article-title":"Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction","volume":"124","author":"Zile","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2019.104577_bib0325","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa052256","article-title":"Trends in prevalence and outcome of heart failure with preserved ejection fraction","volume":"355","author":"Owan","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.104577_bib0330","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1253\/circj.CJ-09-0254","article-title":"Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction. Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD)","volume":"73","author":"Tsuchihashi-Makaya","year":"2009","journal-title":"Circ. J."},{"key":"10.1016\/j.phrs.2019.104577_bib0335","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1200\/JCO.2009.27.3615","article-title":"Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation","volume":"28","author":"Cardinale","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2019.104577_bib0340","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1161\/CIRCIMAGING.112.973321","article-title":"Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab","volume":"5","author":"Sawaya","year":"2012","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"10.1016\/j.phrs.2019.104577_bib0345","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jacc.2013.10.061","article-title":"Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab","volume":"63","author":"Ky","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2019.104577_bib0350","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41598-017-00075-1","article-title":"Candidate gene association studies of anthracycline-induced cardiotoxicity: a systematic review and meta-analysis","volume":"7","author":"Leong","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2019.104577_bib0355","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.jchf.2018.08.005","article-title":"Frequency of transition from stage a to stage B heart failure after initiating potentially cardiotoxic chemotherapy","volume":"6","author":"Jones","year":"2018","journal-title":"JACC Heart Fail."},{"key":"10.1016\/j.phrs.2019.104577_bib0360","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.jcmg.2018.06.005","article-title":"Cardiotoxicity and cardiac monitoring among chemotherapy-treated breast cancer patients","volume":"11","author":"Henry","year":"2018","journal-title":"JACC Cardiovasc. Imaging"},{"key":"10.1016\/j.phrs.2019.104577_bib0365","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4048\/jbc.2017.20.1.82","article-title":"Cardioprotective effect of Dexrazoxane in patients with HER2-Positive breast cancer who receive anthracycline based adjuvant chemotherapy followed by trastuzumab","volume":"20","author":"Kim","year":"2017","journal-title":"J. Breast Cancer"},{"key":"10.1016\/j.phrs.2019.104577_bib0370","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3109\/10976640009148691","article-title":"Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance","volume":"2","author":"Bellenger","year":"2000","journal-title":"J. Cardiovasc. Magn. Reson."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819313271?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819313271?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:06:17Z","timestamp":1760911577000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661819313271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":74,"alternative-id":["S1043661819313271"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2019.104577","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of cardioprotective agents on chemotherapy-induced heart failure: A systematic review and network meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2019.104577","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104577"}}